Results 41 to 50 of about 3,814,825 (281)
Molecules, 2023 Antiplatelet aggregation agents have demonstrated clinical benefits in the treatment of ischemic stroke. In our study, a series of novel nitric oxide (NO)-donating ligustrazine derivatives were designed and synthesized as antiplatelet aggregation agents.
Han-Xu Li +4 more
doaj +1 more source
Use of Antiplatelet Agents and Survival of Tuberculosis Patients: A Population-Based Cohort Study
Journal of Clinical Medicine, 2019 While evidence is accumulating that platelets contribute to tissue destruction in tuberculosis (TB) disease, it is still not known whether antiplatelet agents are beneficial to TB patients.
Meng-Rui Lee +7 more
semanticscholar +1 more source
Advancing Stroke Clinical Trials Using Community Engagement and Implementation Science Approaches
Annals of Clinical and Translational Neurology, EarlyView.ABSTRACT Stroke clinical trials are essential for advancing stroke care but can face challenges with recruitment, retention, clinical relevance, and translation into real‐world practice. We propose that integrating community engagement and implementation science approaches into stroke trials can help address these needs.
Lesli E. Skolarus +2 more
wiley +1 more source
Arthritis Care &Research, EarlyView.Objective The concern that nonsteroidal anti‐inflammatory drugs (NSAIDs) may precipitate flares of inflammatory bowel disease (IBD) has limited their use in managing musculoskeletal symptoms in those with IBD, but safety data are mixed. Methods This retrospective cohort study included patients with IBD aged at least 18 years from Optum's deidentified ...
Adam S. Mayer +4 more
wiley +1 more source
International Journal of Gerontology, 2014 Background: The effect of antiplatelet agents for the treatment of acute stroke is less certain than that for the treatment of acute myocardial ischemia.
Yong Zhang +11 more
doaj +1 more source
Frontiers in Cardiovascular Medicine, 2022 Antiplatelet agents, with aspirin and P2Y12 receptor antagonists as major key molecules, are currently the cornerstone of pharmacological treatment of atherothrombotic events including a variety of cardio- and cerebro-vascular as well as peripheral ...
Georges Jourdi +9 more
doaj +1 more source
American Journal of Medicine, 2019 PURPOSE Patients with nonvalvular atrial fibrillation commonly have comorbidities requiring concurrent use of oral anticoagulants and antiplatelets. There are no real-world data on the comparative safety of concomitant antithrombotic treatments in the ...
A. Douros +5 more
semanticscholar +1 more source
Selective Inhibition of Integrin β3 Topology Provides a Safer Antithrombotic Strategy
Advanced Science, EarlyView.Current integrin αIIbβ3 inhibitors effectively reduce thrombosis but also increase bleeding risk. During thrombosis, high shear blood flow can directly activate the integrin αIIbβ3 via a distinct topological change in the β3 transmembrane domain, independent of hemostatic platelet signaling.
Joonha Lee +11 more
wiley +1 more source
Circulation: Arrhythmia and Electrophysiology, 2019 BACKGROUND Oral anticoagulant use is common among patients undergoing pacemaker or defibrillator surgery. BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial; NCT00800137) demonstrated that perioperative warfarin ...
V. Essebag +26 more
semanticscholar +1 more source
FGL2‐HDAC11 Drives Immunothrombosis via NETs‐Mediated Endothelial Capillarization in MASLD Fibrosis
Advanced Science, EarlyView.ABSTRACT Metabolic dysfunction–associated steatotic liver disease (MASLD) is frequently accompanied by hepatic fibrosis and systemic cardiovascular complications; however, the mechanistic interplay between coagulation abnormalities and disease progression remains poorly defined.
Xitang Li +16 more
wiley +1 more source